Outcome of Board Meeting

BDL/PKL/SEC/2026-27 22 nd October, 2026 National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor Plot no. C/l, G Block Bandra-Kurla Complex, Bandra (E) Mumbai — 400 051. SYMBOL-BETA Sub: Outcome of Board Meeting of Beta Drugs Limited-22nd October, 2026 With reference to above captioned subject matter we would like to inform you that Board of Directors of Beta Drugs Limited in their meeting held today i.e. 22nd October, 2026, at 9:00 AM at the Corporate Office of the company situated at SCO-184, Sector-5, Panchkula-134114 has considered and approved the following agenda items:- 1. The un-audited Standalone & Consolidated financial results alongwith limited review report under regulation 33 of SEBI (LODR) Regulation, 2015 for the Quarter & half year ended 30th September, 2026. Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following documents: 1. Management Discussion & Analysis. 2. Limited review Report on Consolidated Financial Results alongwith Un-Audited Consolidated Financial Results for the quarter & half year ended 30th September, 2026. 3. Limited review Report on Standalone Financial Results alongwith Un-Audited Standalone Financial Results for the quarter & half year ended 30th September, 2026 4. Certificate as per regulation 33(2)(a) & 33(3)(d) of SEBI (LODR) Regulations, 2015 The meeting of the Board of Directors commenced at 9.00 a.m. and concluded at 11:05 a.m. This is for your information and appropriate dissemination. Thanking You Your’s faithfully For Beta Drugs Ltd. Rajni Brar Company Secretary nt Discussion & Beta recorded another strong quarter with impressive performance across its key businesses. Despite gtobat headwinds, the Company demonstrated exceptionat operating performance and is on track for a sustained growth in the medium term. Consotidated revenues from operations for the first six months of FY27 grew by 29.200/o to INR 263.04 Crs. compared to INR 203.6 Crs. in the same period last year. The Branded Oncotogy segment grew by 17o/o.The growth was impacted by production shutdown due to debottlenecking and capacity expansion at Adtey Formutation Ptant. Sates were atso hampered by suppty constraints in ptatin APls; consequentty, the orders have moved to H2 of FY27.The Company expects to close FY27 Branded Oncology at INR 150 Crs. in tine with the guidance. The Branded Oncotogy segment is poised for a sustained growth of 2Oo/o-22o/o over the medium term supported by acceterated new product taunches and stronger brand adoption by oncotogists. We have evaluated the recent NPPA notification retated to trade margin capping at 30%o and are of the view that the recent amendments have no significant bearing on our realisations and / or our margins. We maintain our growth guidance for Branded Oncotogy and CMO in tight of the recent NPPA guidetines The company's growth was led by a 217o rise in CMO business. The high growth was on the back of new customer additions and inctusion of new products devetoped by Beta and offered to new and existing customers. Nivan detivered an exceptional performance in H1FY27, recording a pro-forma groMh otTSo/o. The groMh was aided by deeper penetration of key brands and increasing acceptability among prescribers. Nivian's strategy of focused brand buitding among doctors witnessed stronger traction and the company has entered into marquee IVF chains as a supptier of key products. Exports segment rebounded in Q2 detivering 950/o growth in Q2-FY'27. The Company fited 59 dossiers across setect markets of LATAM, MENA, APAC in H1FY27 tayingthe foundation forfuture growth. In Derma segment Beta signed an exctusive ticensing agreement with Frezyderm for India market for high end cosmeceuticaI products. API segment witnessed strong growth lor H1 Fy,27 at29o/o with the additionat capacity expected to go onstre amin e4Fy27. The Gross margins expanded by486 basis points to 56.21o/oinH1Fy27 compared to 51.35% in H1FY26. The improvement in Gross Margins is a reftection of higher reatisations across businesses. Going forward we expect to maintain the Gross Margin tevets through cost reduction efforts which witt be supplemented by backward integration at our API ptant. Consotidated EBITDA stood at INR 61 Crs. compared to INR 47 Crs. for H1 FY26 growin flby -3Oo/o.ln terms of CIN No.: L24230HP2005P1C028969 Admin. Office : SCO 184, Sector-S, Panchkula-134-114 Haryana (lNDlA) Phone. +91-172-2585481-482-483 Registered Office &Works:Vill. Nandpur, Lodhimajra Road, Tehsil.:Baddi, Distt. Solan, H.P. Phone No.:01795-236196 Website - www. betadrugslimited.com E-Mail :- info@betadrugslimited.com margins, the EBITDA margins increased from 23.08o/o to 23.180/o (inct. other income). PAT (exctuding minority interest) was at INR 34.3 Crs. in H1FY27 compared to Rs. 23.9 Crs. for the corresponding period last year and INR 41.4 Crs. for the whote of FY26. The backward integration at the API ptant is progressing as per the schedute and the commercial production is expected to commence in Q4FY27. The new capacity and the backward integration are expected to reduce dependency on imports and enabte the Company to compty with regutated market guidetines for product registrations. The backward integration is atso expected to aid in margin improvement going forward. This witt further strengthen the company's abitity to produce robust DMFs for regutated markets and facititate quicker, more effective dossier submissions. Outlook The management expects to close FY27 et INR 535+ Crs. for FY27,with EBITDA margins aI23o/o- 240lo resutting in a much stronger H2FY27 compared to H1. The Company expects to maintain the growth momentum in Branded Oncotogy with growth outtook of >2Oo/o over the medium term. During H1FY27, the Company launched 4 new products in Branded Oncotogy of which, 1 was a NDDS and 3 were new formutations, reinforcing our position as the first-to-market company for new products. The company targets to [aunch atteast 4 more products in H2FY27 inctuding Novet formutations and has a pipetine of 15+ products under development for launch over the next 2 years In exports segment, the Company is on track to detiver robust consistent groMh with commerciatisation of approved products. During H1FY27, Beta fited 76 new product dossiers across setect export markets taking the totat registrations to 415 with more than 800 products under different stages of devetopment and expected to be fited over the next 2 years. For Fy27, we expect a growth of 30%o driven by existing order book and expected tender wins for our approved products. At Nivian, we expanded our penetration into IVF chains with sates to organised chains comprising -25o/o of total sates. We expect to launch 2 additionat products in H2FY27 to propet our growth >500/o tor FY27. Nivian has considerabte room for future expansion as the current doctor coverage is about 600/o and the increasing acceptance of Company's brands provide a buoyant growth outtook for the business over the next 2-3 years. Derma business is expected to rebound in H2FY27 as the redressaI of suppty chain disruptions make way for higher primary sates teading to acceterated growth through our distribution network. The Company expects to detiver a growth of 20o/olor FY27 and is on track to achieve the target basis current monthty run rate of INR 2 Crs. The secondary sates for the period H1 Fy27 has grown by 30o/o over H1FY26 GIN No.: L24230HP2005P1C028969 Admin. Office : SCO 184, Sector-S, Panchkula-134-114 Haryana (lNDIA) Phone. +91-172-2585481-482-483 Registered Office &Works:Vill. Nandpur, Lodhimajra Road, Tehsil. :Baddi, Distt. Solan, H.P. Phone No. :01295-236196 Website : - www.betadrugslimited.com E-Mail :- info@betadrugslimited.com Our investments in R&D and product innovation continue to fuetthe growth in oncotogy at Beta and position the Company as a premier Oncotogy company. We expect to launch -15 new products inctud [Showing first 8,000 characters — download PDF for full document]